Can Fite Biopharma W10 (CNFI_t10) SWOT Analysis / TOWS Matrix / MBA Resources
Strategy / MBA Resources
Introduction to SWOT Analysis
SWOT Analysis / TOWS Matrix for Can Fite Biopharma W10 (Israel)
Based on various researches at Oak Spring University , Can Fite Biopharma W10 is operating in a macro-environment that has been destablized by – cloud computing is disrupting traditional business models, talent flight as more people leaving formal jobs, banking and financial system is disrupted by Bitcoin and other crypto currencies, increasing energy prices, central banks are concerned over increasing inflation, competitive advantages are harder to sustain because of technology dispersion, there is backlash against globalization,
increasing household debt because of falling income levels, supply chains are disrupted by pandemic , etc
Introduction to SWOT Analysis of Can Fite Biopharma W10
SWOT stands for an organization’s Strengths, Weaknesses, Opportunities and Threats . At Oak Spring University, we believe that Can Fite Biopharma W10 can use SWOT analysis as a strategic management tool to assess the current internal strengths and weaknesses of the Can Fite Biopharma W10, and to figure out the opportunities and threats in the macro environment – technological, environmental, political, economic, social, demographic, etc in which Can Fite Biopharma W10 operates in.
According to Harvard Business Review, 75% of the managers use SWOT analysis for various purposes such as – evaluating current scenario, strategic planning, new venture feasibility, personal growth goals, new market entry, Go To market strategies, portfolio management and strategic trade-off assessment, organizational restructuring, etc.
SWOT Objectives / Importance of SWOT Analysis and SWOT Matrix
SWOT analysis of Can Fite Biopharma W10 can be done for the following purposes –
1. Strategic planning of Can Fite Biopharma W10
2. Improving business portfolio management of Can Fite Biopharma W10
3. Assessing feasibility of the new initiative in Israel
4. Making a sector specific business decision
5. Set goals for the organization
6. Organizational restructuring of Can Fite Biopharma W10
Strengths of Can Fite Biopharma W10 | Internal Strategic Factors
What are Strengths in SWOT Analysis / TOWS Matrix / Weighted SWOT Analysis
The strengths of Can Fite Biopharma W10 are -
Effective Research and Development (R&D)
– Can Fite Biopharma W10 has innovation driven culture where significant part of the revenues are spent on the research and development activities. This has resulted in – Can Fite Biopharma W10 staying ahead in the industry in terms of – new product launches, superior customer experience, highly competitive pricing strategies, and great returns to the shareholders.
Digital Transformation in industry
- digital transformation varies from industry to industry. For Can Fite Biopharma W10 digital transformation journey comprises differing goals based on market maturity, customer technology acceptance, and organizational culture. Can Fite Biopharma W10 has successfully integrated the four key components of digital transformation – digital integration in processes, digital integration in marketing and customer relationship management, digital integration into the value chain, and using technology to explore new products and market opportunities.
Strong track record of project management in the industry
– Can Fite Biopharma W10 is known for sticking to its project targets. This enables the firm to manage – time, project costs, and have sustainable margins on the projects.
Learning organization
- Can Fite Biopharma W10 is a learning organization. It has inculcated three key characters of learning organization in its processes and operations – exploration, creativity, and expansiveness. The work place at Can Fite Biopharma W10 is open place that encourages instructiveness, ideation, open minded discussions, and creativity. Employees and leaders at Can Fite Biopharma W10 emphasize – knowledge, initiative, and innovation.
Successful track record of launching new products
– Can Fite Biopharma W10 has launched numerous new products in last few years, keeping in mind evolving customer preferences and competitive pressures. Can Fite Biopharma W10 has effective processes in place that helps in exploring new product needs, doing quick pilot testing, and then launching the products quickly using its extensive distribution network.
Innovation driven organization
– Can Fite Biopharma W10 is one of the most innovative firm in sector.
High brand equity
– Can Fite Biopharma W10 has strong brand awareness and brand recognition among both - the exiting customers and potential new customers. Strong brand equity has enabled Can Fite Biopharma W10 to keep acquiring new customers and building profitable relationship with both the new and loyal customers.
Analytics focus
– Can Fite Biopharma W10 is putting a lot of focus on utilizing the power of analytics in business decision making. This has put it among the leading players in the industry. The technology infrastructure of Israel is also helping it to harness the power of analytics for – marketing optimization, demand forecasting, customer relationship management, inventory management, information sharing across the value chain etc.
Cross disciplinary teams
– Horizontal connected teams at the Can Fite Biopharma W10 are driving operational speed, building greater agility, and keeping the organization nimble to compete with new competitors. It helps are organization to ideate new ideas, and execute them swiftly in the marketplace.
High switching costs
– The high switching costs that Can Fite Biopharma W10 has built up over years in its products and services combo offer has resulted in high retention of customers, lower marketing costs, and greater ability of the firm to focus on its customers.
Diverse revenue streams
– Can Fite Biopharma W10 is present in almost all the verticals within the industry. This has provided Can Fite Biopharma W10 a diverse revenue stream that has helped it to survive disruptions such as global pandemic in Covid-19, financial disruption of 2008, and supply chain disruption of 2021.
Training and development
– Can Fite Biopharma W10 has one of the best training and development program in industry. The effectiveness of the training programs can be measured in – employees retention, in-house promotion, loyalty, new venture initiation, lack of conflict, and high level of both employees and customer engagement.
Weaknesses of Can Fite Biopharma W10 | Internal Strategic Factors
What are Weaknesses in SWOT Analysis / TOWS Matrix / Weighted SWOT Analysis
The weaknesses of Can Fite Biopharma W10 are -
Slow to harness new channels of communication
– Even though competitors are using new communication channels such as Instagram, Tiktok, and Snap, Can Fite Biopharma W10 is slow explore the new channels of communication. These new channels of communication can help Can Fite Biopharma W10 to provide better information regarding products and services. It can also build an online community to further reach out to potential customers.
Increasing silos among functional specialists
– The organizational structure of Can Fite Biopharma W10 is dominated by functional specialists. It is not different from other players in the industry, but Can Fite Biopharma W10 needs to de-silo the office environment to harness the true potential of its workforce. Secondly the de-silo will also help Can Fite Biopharma W10 to focus more on services in the industry rather than just following the product oriented approach.
Products dominated business model
– Even though Can Fite Biopharma W10 has some of the most successful models in the industry, this business model has made each new product launch extremely critical for continuous financial growth of the organization. Can Fite Biopharma W10 should strive to include more intangible value offerings along with its core products and services.
Need for greater diversity
– Can Fite Biopharma W10 has taken concrete steps on diversity, equity, and inclusion. But the efforts so far has resulted in limited success. It needs to expand the recruitment and selection process to hire more people from the minorities and underprivileged background.
High dependence on existing supply chain
– The disruption in the global supply chains because of the Covid-19 pandemic and blockage of the Suez Canal illustrated the fragile nature of Can Fite Biopharma W10 supply chain. Even after few cautionary changes, Can Fite Biopharma W10 is still heavily dependent upon the existing supply chain. The existing supply chain though brings in cost efficiencies but it has left Can Fite Biopharma W10 vulnerable to further global disruptions in South East Asia.
Skills based hiring in industry
– The stress on hiring functional specialists at Can Fite Biopharma W10 has created an environment where the organization is dominated by functional specialists rather than management generalist. This has resulted into product oriented approach rather than marketing oriented approach or consumers oriented approach.
Interest costs
– Compare to the competition, Can Fite Biopharma W10 has borrowed money from the capital market at higher rates. It needs to restructure the interest payment and costs so that it can compete better and improve profitability.
High operating costs
– Compare to the competitors, Can Fite Biopharma W10 has high operating costs in the industry. This can be harder to sustain given the new emerging competition from nimble players who are using technology to attract Can Fite Biopharma W10 lucrative customers.
Capital Spending Reduction
– Even during the low interest decade, Can Fite Biopharma W10 has not been able to do capital spending to the tune of the competition. This has resulted into fewer innovations and company facing stiff competition from both existing competitors and new entrants who are disrupting the industry using digital technology.
Low market penetration in new markets
– Outside its home market of Israel, Can Fite Biopharma W10 needs to spend more promotional, marketing, and advertising efforts to penetrate international markets.
Compensation and incentives
– The revenue per employee of Can Fite Biopharma W10 is just above the industry average. It needs to redesign the compensation structure and incentives to increase the revenue per employees. Some of the steps that it can take are – hiring more specialists on project basis, etc.
Can Fite Biopharma W10 Opportunities | External Strategic Factors
What are Opportunities in the SWOT Analysis / TOWS Matrix / Weighted SWOT Analysis
The opportunities of Can Fite Biopharma W10 are -
Changes in consumer behavior post Covid-19
– consumer behavior has changed in the industry because of Covid-19 restrictions. Some of this behavior will stay once things get back to normal. Can Fite Biopharma W10 can take advantage of these changes in consumer behavior to build a far more efficient business model. For example consumer regular ordering of products can reduce both last mile delivery costs and market penetration costs. Can Fite Biopharma W10 can further use this consumer data to build better customer loyalty, provide better products and service collection, and improve the value proposition in inflationary times.
Increase in government spending
– As the United States and other governments are increasing social spending and infrastructure spending to build economies post Covid-19, Can Fite Biopharma W10 can use these opportunities to build new business models that can help the communities that Can Fite Biopharma W10 operates in. Secondly it can use opportunities from government spending in sector.
Learning at scale
– Online learning technologies has now opened space for Can Fite Biopharma W10 to conduct training and development for its employees across the world. This will result in not only reducing the cost of training but also help employees in different part of the world to integrate with the headquarter work culture, ethos, and standards.
Finding new ways to collaborate
– Covid-19 has not only transformed business models of companies in industry, but it has also influenced the consumer preferences. Can Fite Biopharma W10 can tie-up with other value chain partners to explore new opportunities regarding meeting customer demands and building a rewarding and engaging relationship.
Lowering marketing communication costs
– 5G expansion will open new opportunities for Can Fite Biopharma W10 in the field of marketing communication. It will bring down the cost of doing business, provide technology platform to build new products in the industry, and it will provide faster access to the consumers.
Identify volunteer opportunities
– Covid-19 has impacted working population in two ways – it has led to people soul searching about their professional choices, resulting in mass resignation. Secondly it has encouraged people to do things that they are passionate about. This has opened opportunities for businesses to build volunteer oriented socially driven projects. Can Fite Biopharma W10 can explore opportunities that can attract volunteers and are consistent with its mission and vision.
Building a culture of innovation
– managers at Can Fite Biopharma W10 can make experimentation a productive activity and build a culture of innovation using approaches such as – mining transaction data, A/B testing of websites and selling platforms, engaging potential customers over various needs, and building on small ideas in the industry.
Redefining models of collaboration and team work
– As explained in the weaknesses section, Can Fite Biopharma W10 is facing challenges because of the dominance of functional experts in the organization. Can Fite Biopharma W10 can utilize new technology in the field of industry to build more coordinated teams and streamline operations and communications using tools such as CAD, Zoom, etc.
Developing new processes and practices
– Can Fite Biopharma W10 can develop new processes and procedures in industry using technology such as automation using artificial intelligence, real time transportation and products tracking, 3D modeling for concept development and new products pilot testing etc.
Reforming the budgeting process
- By establishing new metrics that will be used to evaluate both existing and potential projects Can Fite Biopharma W10 can not only reduce the costs of the project but also help it in integrating the projects with other processes within the organization.
Remote work and new talent hiring opportunities
– The widespread usage of remote working technologies during Covid-19 has opened opportunities for Can Fite Biopharma W10 to expand its talent hiring zone. According to McKinsey Global Institute, 20% of the high end workforce in fields such as finance, information technology, can continously work from remote local post Covid-19. This presents a really great opportunity for Can Fite Biopharma W10 to hire the very best people irrespective of their geographical location.
Creating value in data economy
– The success of analytics program of Can Fite Biopharma W10 has opened avenues for new revenue streams for the organization in industry. This can help Can Fite Biopharma W10 to build a more holistic ecosystem for Can Fite Biopharma W10 products in the industry by providing – data insight services, data privacy related products, data based consulting services, etc.
Buying journey improvements
– Can Fite Biopharma W10 can improve the customer journey of consumers in the industry by using analytics and artificial intelligence. It can provide automated chats to help consumers solve their own problems, provide online suggestions to get maximum out of the products and services, and help consumers to build a community where they can interact with each other to develop new features and uses.
Threats Can Fite Biopharma W10 External Strategic Factors
What are Threats in the SWOT Analysis / TOWS Matrix / Weighted SWOT Analysis
The threats of Can Fite Biopharma W10 are -
Stagnating economy with rate increase
– Can Fite Biopharma W10 can face lack of demand in the market place because of Fed actions to reduce inflation. This can lead to sluggish growth in the economy, lower demands, lower investments, higher borrowing costs, and consolidation in the industry.
High level of anxiety and lack of motivation
– the Great Resignation in United States is the sign of broader dissatisfaction among the workforce in United States. Can Fite Biopharma W10 needs to understand the core reasons impacting the industry. This will help it in building a better workplace.
Increasing wage structure of Can Fite Biopharma W10
– Post Covid-19 there is a sharp increase in the wages especially in the jobs that require interaction with people. The increasing wages can put downward pressure on the margins of Can Fite Biopharma W10.
Technology disruption because of hacks, piracy etc
– The colonial pipeline illustrated, how vulnerable modern organization are to international hackers, miscreants, and disruptors. The cyber security interruption, data leaks, etc can seriously jeopardize the future growth of the organization.
Environmental challenges
– Can Fite Biopharma W10 needs to have a robust strategy against the disruptions arising from climate change and energy requirements. EU has identified it as key priority area and spending 30% of its 880 billion Euros European post Covid-19 recovery funds on green technology. Can Fite Biopharma W10 can take advantage of this fund but it will also bring new competitors in the industry.
Consumer confidence and its impact on Can Fite Biopharma W10 demand
– There is a high probability of declining consumer confidence, given – high inflammation rate, rise of gig economy, lower job stability, increasing cost of living, higher interest rates, and aging demography. All the factors contribute to people saving higher rate of their income, resulting in lower consumer demand in industry and other sectors.
Aging population
– As the populations of most advanced economies are aging, it will lead to high social security costs, higher savings among population, and lower demand for goods and services in the economy. The household savings in US, France, UK, Germany, and Japan are growing faster than predicted because of uncertainty caused by pandemic.
Regulatory challenges
– Can Fite Biopharma W10 needs to prepare for regulatory challenges as consumer protection groups and other pressure groups are vigorously advocating for more regulations on big business - to reduce inequality, to create a level playing field, to product data privacy and consumer privacy, to reduce the influence of big money on democratic institutions, etc. This can lead to significant changes in the industry regulations.
Instability in the European markets
– European Union markets are facing three big challenges post Covid – expanded balance sheets, Brexit related business disruption, and aggressive Russia looking to distract the existing security mechanism. Can Fite Biopharma W10 will face different problems in different parts of Europe. For example it will face inflationary pressures in UK, France, and Germany, balance sheet expansion and demand challenges in Southern European countries, and geopolitical instability in the Eastern Europe.
Technology acceleration in Forth Industrial Revolution
– Can Fite Biopharma W10 has witnessed rapid integration of technology during Covid-19 in the industry. As one of the leading players in the industry, Can Fite Biopharma W10 needs to keep up with the evolution of technology in the sector. According to Mckinsey study top managers believe that the adoption of technology in operations, communications is 20-25 times faster than what they planned in the beginning of 2019.
Barriers of entry lowering
– As technology is more democratized, the barriers to entry to industry are lowering. It can presents Can Fite Biopharma W10 with greater competitive threats in the near to medium future. Secondly it will also put downward pressure on pricing throughout the sector.
Backlash against dominant players
– US Congress and other legislative arms of the government are getting tough on big business especially technology companies. The digital arm of Can Fite Biopharma W10 business can come under increasing regulations regarding data privacy, data security, etc.
High dependence on third party suppliers
– Can Fite Biopharma W10 high dependence on third party suppliers can disrupt its processes and delivery mechanism. For example -the current troubles of car makers because of chip shortage is because the chip companies started producing chips for electronic companies rather than car manufacturers.
Weighted SWOT Analysis of Can Fite Biopharma W10 Template, Example
Not all factors mentioned under the Strengths, Weakness, Opportunities, and Threats quadrants in the SWOT Analysis are equal. Managers at Can Fite Biopharma W10 needs to zero down on the relative importance of each factor mentioned in the Strengths, Weakness, Opportunities, and Threats quadrants.
We can provide the relative importance to each factor by assigning relative weights. Weighted SWOT analysis process is a three stage process –
First stage for doing weighted SWOT analysis of Can Fite Biopharma W10 is to rank the strengths and weaknesses of the organization. This will help you to assess the most important strengths and weaknesses of the firm and which one of the strengths and weaknesses mentioned in the initial lists are marginal and can be left out.
Second stage for conducting weighted SWOT analysis of Can Fite Biopharma W10 is to give probabilities to the external strategic factors thus better understanding the opportunities and threats arising out of macro environment changes and developments.
Third stage of constructing weighted SWOT analysis of Can Fite Biopharma W10 to provide strategic recommendations includes – joining likelihood of external strategic factors such as opportunities and threats to the internal strategic factors – strengths and weaknesses. You should start with external factors as they will provide the direction of the overall industry. Secondly by joining probabilities with internal strategic factors can help the company not only strategic fit but also the most probably strategic trade-off that Can Fite Biopharma W10 needs to make to build a sustainable competitive advantage.
